DeBruyne L A, Magee J C, Buelow R, Bromberg J S
Department of Surgery, University of Michigan Medical Center, Ann Arbor 48109, USA.
Transplantation. 2000 Jan 15;69(1):120-8. doi: 10.1097/00007890-200001150-00021.
Decapeptides derived from human HLA class I sequences have been shown to prolong allograft survival. The mechanism of action of these peptides has been uncertain, because they act in an MHC unrestricted manner. Recently, it was found that these peptides bind heme oxygenase 1 (HO-1). In the present study, we sought to determine whether local delivery of these peptides through gene transfer could extend allograft survival, and to explore the underlying mechanisms.
C57BL/6 neonatal hearts were transplanted to CBA/J recipients and the peptide, or plasmid DNA encoding the peptide, was injected directly into the allograft at the time of the transplant.
Direct injection of 1 microg of the B2702 peptide into the allograft did not prolong survival (13.3+/-0.8 vs. 13.4+/-0.8 days for untreated controls), but injection of 400 microg of peptide did extend survival (22.0+/-0.6). Injection of plasmid DNA encoding the B2702 peptide was superior to peptide delivery, extending graft survival to 30.8+/-1.5 days. Similar results were obtained using another plasmid encoding the rationally designed peptide BC1 (28.5+/-1.7), whereas no significant prolongation was observed using a plasmid encoding the control peptide B2705 (16.5+/-1.0). To explore the hypothesis that these peptides exert their immunosuppressive effect by altering HO-1 activity, animals were treated with iron protoporphyrin, an inducer of HO-1 activity, or tin protoporphyrin, an inhibitor of HO-1. Treatment with iron protoporphyrin alone extended graft survival (24.5+/-1.6) and did not alter the benefit in survival seen with BC1 gene transfer (28.0+/-0.8). In contrast, treatment with tin protoporphyrin abolished the benefit of BC1 gene transfer (17.0+/-0.6).
These results demonstrate that plasmid mediated gene transfer is an effective means for delivering immunosuppressive peptides to extend allograft survival. The experiments suggest that these peptides may act by increasing HO-1 activity and support a role for HO-1 in immune regulation and allograft survival.
源自人类HLA I类序列的十肽已被证明可延长同种异体移植物的存活时间。这些肽的作用机制尚不确定,因为它们以MHC非限制性方式起作用。最近,发现这些肽可结合血红素加氧酶1(HO-1)。在本研究中,我们试图确定通过基因转移局部递送这些肽是否能延长同种异体移植物的存活时间,并探索其潜在机制。
将C57BL/6新生小鼠心脏移植到CBA/J受体中,并在移植时将肽或编码该肽的质粒DNA直接注射到同种异体移植物中。
将1微克B2702肽直接注射到同种异体移植物中并未延长存活时间(未处理对照组为13.3±0.8天,而处理组为13.4±0.8天),但注射400微克肽确实延长了存活时间(22.0±0.6天)。注射编码B2702肽的质粒DNA优于肽递送,可将移植物存活时间延长至30.8±1.5天。使用另一种编码合理设计的肽BC1的质粒也得到了类似结果(28.5±1.7天),而使用编码对照肽B2705的质粒未观察到明显的延长(16.5±1.0天)。为了探讨这些肽通过改变HO-1活性发挥免疫抑制作用的假设,用HO-1活性诱导剂铁卟啉或HO-1抑制剂锡卟啉对动物进行处理。单独用铁卟啉处理可延长移植物存活时间(24.5±1.6天),且不改变BC1基因转移所观察到的存活益处(28.0±0.8天)。相反,用锡卟啉处理消除了BC1基因转移的益处(17.0±0.6天)。
这些结果表明,质粒介导的基因转移是递送免疫抑制肽以延长同种异体移植物存活时间的有效手段。实验表明,这些肽可能通过增加HO-1活性发挥作用,并支持HO-1在免疫调节和同种异体移植物存活中的作用。